Background Eisenmenger syndrome (ES) is a severe and fatal complication of uncorrected congenital heart disease characterised ...

FDA label expansion makes selumetinib the second MEK inhibitor approved for adults with neurofibromatosis type 1-associated ...

The FDA has granted Fast Track designation to VS-041, an investigational therapy for the treatment of heart failure with preserved ejection fraction.

A trial emulation assessed whether GLP-1RA use improves cardiovascular, kidney, and death outcomes in patients with systemic lupus erythematosus, including lupus nephritis.

ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...